» Articles » PMID: 34806168

Disparities and Trends in the Participation of Minorities, Women, and the Elderly in Breast, Colorectal, Lung, and Prostate Cancer Clinical Trials

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2021 Nov 22
PMID 34806168
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study was done to determine the representation of minorities, women, and the elderly in National Cancer Institute (NCI) clinical trials.

Methods: This is an analysis in the NCI Clinical Data Update System. Patients were evaluated in breast, colorectal, lung, and prostate cancer trials from 2000 to 2019. Representation in a trial was determined by race/ethnicity, sex, and age. Secondarily, the change in trial participation by multivariable analysis by comparing years 2000 through 2004 to 2015 through 2019 was evaluated.

Results: The cohort included 242,720 participants: 197,320 Non-Hispanic White (81.3%), 21,190 Black (8.7%), 11,587 Hispanic (4.8%), and 6880 Asian/Pacific Islander (2.8%). Black and Hispanic patients were underrepresented for colorectal (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.50-0.67; P < .001 and OR, 0.74; 95% CI, 0.64-0.87; P < .001, respectively), lung (OR, 0.83; 95% CI, 0.76-0.91; P < .001 and 0.66; 95% CI, 0.57-0.77; P < .001, respectively), and prostate cancer trials (OR, 0.85; 95% CI, 0.79-0.92; P < .001 and OR, 0.58; 95% CI, 0.51-0.66; P < .001) between 2015 and 2019. The odds of participation in 2015 to 2019 increased among Black patients in breast (OR, 2.19; 95% CI, 2.07-%2.32; P < .001), lung (OR, 1.54; 95% CI, 1.38-1.73; P < .001), and prostate cancer trials (OR, 1.14; 95% CI, 1.04-1.26; P < .001). The odds of participation in a trial among Hispanic patients increased for breast (OR, 3.32; 95% CI, 3.09-3.56; P < .001), colorectal (OR, 2.46; 95% CI, 2.04-2.96; P < .001), lung (OR, 3.88; 95% CI, 3.20-4.69; P < .001), and prostate cancer (OR, 1.70; 95% CI, 1.42-2.04; P = .005).

Conclusions: This study identified that Black and Hispanic patients remain underrepresented in trials, but in recent years, participation has increased. These findings indicate that minority participation has increased over time, but further efforts are needed.

Citing Articles

The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review.

Hanvey G, Johnson H, Cartagena G, Dede D, Krieger J, Ross K J Clin Transl Sci. 2025; 9(1):e25.

PMID: 40052046 PMC: 11883616. DOI: 10.1017/cts.2024.677.


Racial Disparities in Clinical Trial Enrollment Among Patients Diagnosed With Prostate Cancer: A Population-Based Cohort of Oncology Practices.

Wiesen B, Flaig T, Gershman B, Konety B, Warren A, Kuna E Adv Urol. 2024; 2024:8871425.

PMID: 39735345 PMC: 11671626. DOI: 10.1155/aiu/8871425.


Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.

Bain S, Belmar N, Hoff S, Husain M, Rasmussen S, Vilsboll T Diabetes Ther. 2024; 16(1):15-28.

PMID: 39520501 PMC: 11759736. DOI: 10.1007/s13300-024-01659-7.


Navigating the Path to Inclusion: Understanding Barriers and Facilitators to Clinical Trial Participation Among Chinese Older Adults in the United States with Multimorbidity.

Tarn D, Liu R, Pun T, Schwartz J J Gen Intern Med. 2024; 40(2):393-401.

PMID: 39495453 PMC: 11802972. DOI: 10.1007/s11606-024-09162-2.


Prevalence and proportion by age and sex of chronic health conditions in a large healthcare system.

Gronich N, Saliba W, Schwartz J PLoS One. 2024; 19(9):e0308031.

PMID: 39325771 PMC: 11426542. DOI: 10.1371/journal.pone.0308031.